Literature DB >> 8473373

Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies.

A De Bellis1, A Bizzarro, R Rossi, V A Paglionico, T Criscuolo, G Lombardi, A Bellastella.   

Abstract

Idiopathic Addison's disease is a chronic organ-specific autoimmune disorder with a long subclinical period characterized only by the presence of adrenal autoantibodies (AA) with or without adrenal function failure. The aim of this longitudinal study was to evaluate the behavior of AA using, an indirect fluorescence method, and adrenal function in 20 AA-positive and 50 AA-negative patients screened by an investigation of a large population of organ-specific autoimmune disease patients without clinical Addison's disease. As controls, 100 normal age-matched subjects were tested only once. In the 20 AA-positive and 50 negative patients, AA and adrenal functional tests were evaluated every 4 months for 5 yr. The AA-positive patients were grouped into 5 adrenal functional stages, specifically: stage 0, normal adrenal function; stage 1, high PRA and low (or normal) aldosterone levels alone; stage 2, along with impaired cortisol response to ACTH, stage 3, along with increased ACTH levels; and stage 4, clinically overt Addison's disease. On the basis of the behavior of AA, the 20 positive patients were grouped as follows: group A, 11 patients with AA titer of 1:8 or higher at the first observation and persistently AA positive in subsequent observations, with titers ranging from 1:8 to 1:64; group B, 6 patients with initial AA titers of 1:8 or lower and AA disappearance in subsequent observations; and group C, 3 patients with AA titer of 1:32 or higher, undergoing corticosteroid therapy after the start of the study and showing AA disappearance in subsequent observations. With respect to adrenal function in group A, 2 patients initially in stage 1 and 1 patient initially in stage 2 did not progress to the upper stages, whereas 5 patients initially in stage 0 and 3 initially in stage 1 progressed subsequently to the upper stages, in 2 cases reaching overt clinical Addison's disease (stage 4). On the other hand, all of the patients of group B showed both a spontaneous disappearance of AA and recovery of adrenal function during the study span. Also, the 3 patients of group C showed disappearance of AA after corticosteroid therapy with recovery of adrenal function. None of the 50 patients who were initially AA negative became AA positive subsequently or showed impairment of adrenal function. We reached the following conclusions. 1) AA, even if present initially in some subjects without clinical Addison's disease, can subsequently disappear. 2) Restoration of adrenal function after disappearance of AA indicates that a spontaneous remission of subclinical adrenocortical failure can occur.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473373     DOI: 10.1210/jcem.76.4.8473373

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Cortisol Levels in Children With Diabetic Ketoacidosis Associated With New-Onset Type 1 Diabetes Mellitus.

Authors:  Kristen M Williams; Pamela Fazzio; Sharon E Oberfield; Mary P Gallagher; Gaya S Aranoff
Journal:  Clin Pediatr (Phila)       Date:  2017-02       Impact factor: 1.168

2.  Characterization of pituitary cells targeted by antipituitary antibodies in patients with isolated autoimmune diseases without pituitary insufficiency may help to foresee the kind of future hypopituitarism.

Authors:  A De Bellis; A Dello Iacovo; G Bellastella; A Savoia; D Cozzolino; A A Sinisi; A Bizzarro; A Bellastella; D Giugliano
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

3.  Simultaneous evaluation of the circulating levels of both Th1 and Th2 chemokines in patients with autoimmune Addison's disease.

Authors:  G Bellastella; M Rotondi; E Pane; S Costantini; C Colella; R Calemma; F Capone; A Falorni; G Castello; A A Sinisi; A Bizzarro; L Chiovato; A Bellastella; A De Bellis
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

4.  Turner's syndrome mosaicism 45X/47XXX: an interesting natural history.

Authors:  L Tauchmanovà; R Rossi; M Pulcrano; L Tarantino; C Baldi; G Lombardi
Journal:  J Endocrinol Invest       Date:  2001-11       Impact factor: 4.256

5.  Polyendocrinopathy in children, adolescents, and young adults with type 1 diabetes: a multicenter analysis of 28,671 patients from the German/Austrian DPV-Wiss database.

Authors:  Katharina Warncke; Elke E Fröhlich-Reiterer; Angelika Thon; Sabine E Hofer; Dagobert Wiemann; Reinhard W Holl
Journal:  Diabetes Care       Date:  2010-06-14       Impact factor: 19.112

6.  Partial recovery of adrenal function in a patient with autoimmune Addison's disease.

Authors:  L C C J Smans; P M J Zelissen
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

Review 7.  Therapy of adrenal insufficiency: an update.

Authors:  Alberto Falorni; Viviana Minarelli; Silvia Morelli
Journal:  Endocrine       Date:  2012-11-21       Impact factor: 3.633

8.  Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison's disease.

Authors:  Simon H S Pearce; Anna L Mitchell; Stuart Bennett; Phil King; Sukesh Chandran; Sath Nag; Shu Chen; Bernard Rees Smith; John D Isaacs; Bijay Vaidya
Journal:  J Clin Endocrinol Metab       Date:  2012-07-05       Impact factor: 5.958

Review 9.  Autoimmune Addison disease: pathophysiology and genetic complexity.

Authors:  Anna L Mitchell; Simon H S Pearce
Journal:  Nat Rev Endocrinol       Date:  2012-01-31       Impact factor: 43.330

Review 10.  Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Stefan R Bornstein; Bruno Allolio; Wiebke Arlt; Andreas Barthel; Andrew Don-Wauchope; Gary D Hammer; Eystein S Husebye; Deborah P Merke; M Hassan Murad; Constantine A Stratakis; David J Torpy
Journal:  J Clin Endocrinol Metab       Date:  2016-01-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.